Blood cancer applications give a brief discussion and research on Cancer study which aids in curing blood cancer. Leukemia is distinguished by a fast boost in the number of immature blood units. Congesting due to such cells makes the skeletal part marrow incapable to produce healthy blood cells. Lymphoma applications direct remedy is needed in acute leukemia due to the rapid progression and accumulation of the malignant units, which then spill over into the bloodstream and disperse to other organs of the body. Acute types of Lymphoma are the most widespread types of leukemia in children.
Current treatment options comprise of surgery, chemotherapy or radiation plus more recently introduced targeted therapies. Targeted therapies aim to specifically address malignantly transformed cells while sparing healthy tissues. Thus, receptors, which are important during embryonic development and readopted by cancer cells, belong to the most promising targets. One of the most prominent molecules of that kind is the human epidermal growth factor receptor-2 (HER-2). HER-2 is a receptor tyrosine kinase, mediating signals for cell proliferation, cell mobility and survival. In the absence of a known ligand activation is achieved by homo- or heterodimerization. HER-2 is very important during embryonic development, e.g. it plays a role in ductal morphogenesis of the mammary gland, but it is almost not expressed on adult tissue, except the heart. On the contrary, HER-2 is overexpressed in breast, ovarian, gastric, colorectal, pancreatic, and endometrial cancers.
IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach (Erika Jensen-Jarolim)
Last date updated on June, 2014